PipelineHuidaGene has multiple R&D pipelines for ophthalmology and neurology.
-
01Neurology Diseases
MECP2 Duplication Syndrome (MDS)
Huntington's Disease (HD)
Amyotrophic Lateral Sclerosis (ALS)
-
02Ophthalmology Diseases
RPE65 Mutation-Associated Inherited Retinal Dystrophies (RPE65-IRD)
Neovascular Age-related Macular Degeneration (nAMD)
RHO-Associated Retinitis Pigmentosa (RHO-adRP)
-
03Neuromuscular Diseases
-
European Medicines Agency Issues Positive Opinion on HuidaGene's Triple-Designation HG004 Orphan Designation ApplicationJan 08,2025
Learn More
-
HuidaGene Therapeutics Announces Landmark Publication in Nature Neuroscience Highlighting HG204’s Potential as First RNA-editing Therapy for MECP2 Duplication SyndromDec 12,2024
Learn More
-
HuidaGene Therapeutics Initiates M.U.S.C.L.E. Clinical Trial of HG302 for Duchenne Muscular Dystrophy and Completes First Patient DosedDec 12,2024
Learn More